On Dec. 4, 2020, VBI Vaccines and Syneos Health announced a partnership for the commercialization of VBIﾒs 3-antigen prophylactic hepatitis B (HBV) vaccine in the U.S., Europe, and Canada, pending regulatory approvals. VBI and Syneos Health have been working together on the pre-launch strategy and activity since the fourth quarter of 2019.